Front. Immunol.
Frontiers in Immunology
Front. Immunol.
1664-3224
Frontiers Media S.A.
10.3389/fimmu.2023.1345777
Immunology
Correction
Corrigendum: MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction
Medina
Juan Pablo
1
†
Bermejo-Álvarez
Ismael
1
†
Pérez-Baos
Sandra
1
Yáñez
Rosa
2
3
Fernández-García
María
2
3
García-Olmo
Damián
4
5
6
Mediero
Aránzazu
1
Herrero-Beaumont
Gabriel
1
*
Largo
Raquel
1
1
Bone and Joint Research Unit, Rheumatology Dept, IIS-Fundación Jiménez Díaz Universidad Autonoma de Madrid (UAM), Madrid, Spain
2
Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain
3
Advanced Therapies Dept, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
4
New Therapies Laboratory, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
5
Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain
6
Department of Surgery, School of Medicine UAM, Madrid, Spain
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Gabriel Herrero-Beaumont, gherrero@fjd.es
†These authors have contributed equally to this work and share first authorship
06
12
2023
2023
14
1345777
28
11
2023
29
11
2023
Copyright © 2023 Medina, Bermejo-Álvarez, Pérez-Baos, Yáñez, Fernández-García, García-Olmo, Mediero, Herrero-Beaumont and Largo
2023
Medina, Bermejo-Álvarez, Pérez-Baos, Yáñez, Fernández-García, García-Olmo, Mediero, Herrero-Beaumont and Largo
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction by Medina JP, Bermejo-Álvarez I, Pérez-Baos S, Yáñez R, Fernández-García M, García-Olmo D, Mediero A, Herrero-Beaumont G and Largo R (2023). Front. Immunol. 14:1193179. doi: 10.3389/fimmu.2023.1193179
mesenchymal stem cells (MSCs)
innate inflammation
macrophage
polarization
inflammasome
prostaglandin E2
COX-2
section-in-acceptance
Molecular Innate Immunity
In the published article, there was an error in the Funding statement. The funding statement was displayed as “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by Fondo Europeo de Desarrollo Regional (FEDER).” The correct statement is “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by the European Union.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.